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Abstract
Purpose: To determine the effect of different drug-loaded nanocarriers (micelles and liposomes) on delivery and treatment
efficacy for radiofrequency ablation (RFA) combined with nanodrugs.
Materials/Methods: Fischer 344 rats were used (n=196). First, single subcutaneous R3230 tumors or normal liver
underwent RFA followed by immediate administration of IV fluorescent beads (20, 100, and 500 nm), with fluorescent
intensity measured at 4–24 hr. Next, to study carrier type on drug efficiency, RFA was combined with micellar (20 nm) or
liposomal (100 nm) preparations of doxorubicin (Dox; targeting HIF-1a) or quercetin (Qu; targeting HSP70). Animals
received RFA alone, RFA with Lipo-Dox or Mic-Dox (1 mg IV, 15 min post-RFA), and RFA with Lipo-Qu or Mic-Qu given 24 hr
pre- or 15 min post-RFA (0.3 mg IV). Tumor coagulation and HIF-1a orHSP70 expression were assessed 24 hr post-RFA.
Third, the effect of RFA combined with IV Lipo-Dox, Mic-Dox, Lipo-Qu, or Mic-Qu (15 min post-RFA) compared to RFA alone
on tumor growth and animal endpoint survival was evaluated. Finally, drug uptake was compared between RFA/Lipo-Dox
and RFA/Mic-Dox at 4–72 hr.
Results: Smaller 20 nm beads had greater deposition and deeper tissue penetration in both tumor (100 nm/500 nm) and
liver (100 nm) (p,0.05). Mic-Dox and Mic-Qu suppressed periablational HIF-1a or HSP70 rim thickness more than liposomal
preparations (p,0.05). RFA/Mic-Dox had greater early (4 hr) intratumoral doxorubicin, but RFA/Lipo-Dox had progressively
higher intratumoral doxorubicin at 24–72 hr post-RFA (p,0.04). No difference in tumor growth and survival was seen
between RFA/Lipo-Qu and RFA/Mic-Qu. Yet, RFA/Lipo-Dox led to greater animal endpoint survival compared to RFA/Mic-
Dox (p,0.03).
Conclusion: With RF ablation, smaller particle micelles have superior penetration and more effective local molecular
modulation. However, larger long-circulating liposomal carriers can result in greater intratumoral drug accumulation over
time and reduced tumor growth. Accordingly, different carriers provide specific advantages, which should be considered
when formulating optimal combination therapies.
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Introduction
Radiofrequency ablation (RFA) is now a mainstay treatment for
primary and secondary small focal tumors in the liver, lung,
kidney, and other organs, with long-term studies demonstrating
good outcomes in well-selected patient populations [1,2]. Howev-
er, challenges to RF ablation of larger tumors remain, including
the potential persistence of residual tumor cells within the ablation
zone and the surrounding ablative margin despite apparent
adequate treatment [3,4]. Therefore, strategies to target residual
viable tumor cells and achieve a more complete treatment are
being actively pursued. One such strategy has been to combine RF
ablation with chemotherapy delivered in liposomal nanocarriers to
target partially-injured viable cells in the ablation zone and
surrounding periablational rim [5–7]. Early studies demonstrate
increased local tumor coagulation, intratumoral drug accumula-
tion, increased animal endpoint survival, and increased tumor
coagulation in clinical studies using long-circulating liposomal
doxorubicin as an adjuvant to RF [5–9].
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of the RFA-induced tissue reactions and low-level hyperthermia in
the periablational margin has led to refined approaches such as
modulating chemotherapy drug payload, composition, and
liposomal drug release profile [10–15]. Key examples include
the use of liposomal quercetin to eliminate upregulated heat shock
proteins and bortezomib to eliminate HIF-1a and thereby increase
tumor destruction [14,16]. Yet, limitations persist, either in the
form of incomplete modulation of target post-RFA tissue reactions,
inadequate spatial and temporal coordination of drug delivery to
the periablational rim, or sub-optimal drug release [14,17,18].
Specifically, in the case of liposomal quercitin, although marked
reduction in the thickness of the rim of HSP was noted, persistence
of more peripheral expression of HSP was seen. This provides
ample rationale for further study to uncover the optimal
nanocarriers to be used in the setting of ablation.
Most studies have used 100 nm-size liposomal carriers, based
upon original combination therapy studies and the long-circulat-
ing nature of many of these formulations [12,18]. Yet, within the
fields of oncology and pharmacotherapeutics, there is increasing
interest in using smaller carriers (micelles and spheroids) to
improve intratumoral drug delivery and deeper interstitial
penetration on its own, and in combination with low-level
generalized hyperthermic treatments [19,20]. However, such
carrier alterations will likely affect properties of drug delivery
such as kinetics, warranting formal evaluation of potential trade-
offs between different outcomes (e.g., delivery, modulation of
specified targets, and overall survival).
Along these lines, here, we sought to determine whether or not
we could alter the nanodrug formulation to improve the spatial
distribution of specific drugs to target relatively ‘‘short-acting’’
processes in a rim further from the ablation zone that were
inadequately treated using long-circulating liposomes in prior
studies [14,21]. Accordingly, we studied the comparative effects of
smaller (20 nm beads or micelles) and larger–sized (100+ nm
beads or long-circulating PEG-coated liposomes) particles/carri-
ers: on 1) distribution in the periablational rim using fluorescent
beads (to determine the extent to which smaller particles have
deeper penetration in periablational inflammatory tissue; 2)
suppressing key ablation-induced reactions including pro-angio-
genic hypoxia-inducible factor (HIF-1a) and protective heat shock
protein (HSP70) production in the periablational rim using
targeted drug payloads (doxorubicin/Dox and quercetin/Qu); 3)
intratumoral drug accumulation of a target drug payload
(doxorubicin); and finally 4) determine whether any of these
primary end-points ultimately affected tumor growth rate and
animal endpoint survival.
Materials and Methods
Experimental Overview
All animal work was conducted according to relevant national
and international guidelines. Approval of the Beth Israel
Deaconess Medical Center Institutional Animal Care and Use
Committee was obtained prior to the start of this study. The study
was performed in four phases. A total of 196 female Fischer 344
rats were used. All drugs were administered intravenously (IV).
The following abbreviations are used: liposomal doxorubicin
(Lipo-Dox), micellar doxorubicin (Mic-Dox), liposomal quercetin
(Lipo-Qu), and micellar quercetin (Mic-Qu).
Phase1. Effect of particle size on distribution in the
periablational rim after RF ablation. Studies were per-
formed in two models, representing the tumor and the necessary
surrounding normal tissue that must be ablated to achieve an
adequate ablation margin [1]. First, 16 single subcutaneous R3230
breast adenocarcinoma tumors were implanted. Animals were
randomized to receive RFA combined with color-labeled fluores-
cent beads of three sizes (20, 100, and 500 nm) given I5 min post-
RF (6 animals62 time points, n=12) or IV fluorescent beads
treatment alone (control tumors; n=4). Next, the left liver lobes of
16 normal (tumor-free) animals were treated with RF ablation/IV
fluorescent beads (20 nm and 100 nm, 15 min post-RFA) (6
animals62 time points, n=12) and control IV fluorescent beads
alone (control livers; n=4). Animals were sacrificed at 4 and 24 hr
post-treatment, and tissues harvested for histopathologic and
fluorescent microscopic analysis and quantification.
Phase 2. Effect of carrier (20 nm micelles vs. 100 nm
liposomes) on combination therapy (RF ablation with
doxorubicin or quercetin). Seventy single subcutaneous
R3230 tumors were divided into the following 7 treatment arms
(n=10 per group): RF alone, RF ablation with liposomal or
micellar doxorubicin (both formulations: 1 mg in 0.5 ml, given
15 min post-RFA), and RF ablation with either liposomal or
micellar quercetin (each formulation, 0.3 mg in 0.5 ml, given
either 24 hr pre- or 15 min post-RFA based upon prior studies
using these two time points for liposomal quercetin [14]).
Doxorubicin (an HIF-1a inhibitor) and quercetin (an HSP70
inhibitor) were selected as both agents have known suppressive
effects on hypoxia and RF ablation-induced heat stress responses,
respectively [14,22]. Animals were sacrificed and tumors harvested
24 hr post-RFA. Outcome measures included tumor coagulation
and immunohistochemistry (IHC) for HIF-1a and HSP70
(including rim thickness and % cell positivity/high powered field
[hpf]).
Phase 3. Effect of nanocarrier on tumor growth and
survival after RF ablation. A total of 30 single subcutaneous
R3230 tumors were used. Animals were allocated to the following
4 treatment arms: RF ablation with liposomal or micellar
doxorubicin (both formulations: 1 mg in 0.5 ml, given 15 min
post-RFA; n=8 each arm), and RF ablation with either liposomal
or micellar quercetin (each formulation, 0.3 mg in 0.5 ml) given
15 min post-RFA (n=7–8 each arm). The administration time for
RF/quercetin studies was selected based upon the results of Phase
2. Tumor growth was measured daily and animals were sacrificed
at a pre-determined endpoint of 30 mm mean tumor diameter or
60 days survival post-ablation, whichever came first. Outcome
measures included tumor growth curves and Kaplan Meier
analysis of survival rates.
Phase 4. Effect of nanocarrier on intratumoral drug
delivery and retention after RF ablation. Here, 64 paired
subcutaneous R3230 tumors were implanted in 32 animals.
Animals were allocated to the following treatment arms: RF
ablation of one tumor followed by either liposomal doxorubicin or
micellar doxorubicin (IV, 1 mg in 0.5 ml, given 15 min post-
RFA). The second, paired non-ablated tumor served as in internal
control that was exposed to either IV liposomal or micellar
doxorubicin alone. Animals were sacrificed at 4 different time
points (1–72 hr post-RFA), for a total of 64 tumors (n=4
treatments64 time points64 per group). Ablated and unablated
tumors and the left liver lobes were harvested. Outcome measures
included gross and histopathologic evaluation for tumor coagula-
tion, and fluorescent quantitative studies for intratumoral doxo-
rubicin
Animal Models
For all experiments and procedures, anesthesia was induced
with 0.1 ml intraperitoneal (IP) injection of a mixture of ketamine
(100 mg/ml, Ketaject; Phoenix Pharmaceutical, St. Joseph, MO)
Effect of Nanodrug Carrier on RF Tumor Ablation Therapy
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maintain adequate anesthesia, increments of 0.01 ml were used
when necessary. Animals were sacrificed with an overdose of
0.3 ml of the same mixture.
Experiments were performed using two animal tissues. The first
is a well-characterized established R3230 mammary adenocarci-
noma cell line implanted in female Fisher 344 rats (150620 g; 14–
16 weeks old, Charles River, Wilmington, MA) [5,23]. Tumor
implantation, evaluation, and preparation techniques were per-
formed as previously described [5]. Briefly, one tumor was
implanted into each animal by slowly injecting 0.3–0.4 mL of
tumor suspension into the chest mammary fat pad of each animal
via an 18-gauge needle. 1.3–1.5 cm solid non-necrotic tumors
were used (18–21 days after implantation), randomized to different
treatment arms. For Phase 3, the second (remote) tumor was
generated using similar implantation technique, with injection into
the abdominal subcutaneous space 3.5– 4 cm distal to the primary
site of injection in the chest. The second model was normal liver in
Fischer F344 female rats. After anesthesia induction, hair was
removed at the incision site and the skin was cleansed with a
disinfectant (70% EtOH). A 15 mm incision was made in a
subcostal location to expose the left lobe of the liver. After
completion of the procedure, the abdomen was closed in layers
using 4–5 interrupted sutures. All intravenous injections were
administered via IV tail injection, under complete anesthesia.
RF Application
Conventional monopolar RFA was applied by using a 500-kHz
RFA generator (model 3E; Radionics, Burlington, Mass), as has
been previously described [5]. Briefly, the 1-cm tip of a 21-gauge
electrically insulated electrode (SMK electrode; Radionics) was
inserted into the center of the tumor or left liver lobe. RF energy
was applied for 5 min with generator output titrated to maintain a
designated tip temperature (7062uC, continuous monitoring via a
thermocouple in the electrode tip). This standardized method of
RF application has been previously demonstrated to provide
reproducible volumes of coagulation with use of this conventional
RFA system [5,23]. To complete the RF circuit, the animal was
placed on a standardized metallic grounding pad (Radionics).
Preparation and administration of adjuvant nanoagents
For fluorescent beads, three commercially available carboxyl-
ated fluorescent dyed-polystyrene microspheres were used (Fluo-
Spheres; Invitrogen, Eugene, OR), representing three different
sizes/colors: 20 nm/crimson (wavelengths, excitation 625 nm/
emission 645 nm), 100 nm/orange (540/560), and 500 nm/
yellow-green (505/515), which were best observed using the
purple, red, and green microscope color filters, respectively (per
the manufacturer). Prior to initiating our experiments, single-
colored beads were used as positive controls and examined under
all fluorescent filters to ensure absence of any fluorescence bleed-
through artifacts.
For liposomal doxorubicin, a commercially available prepara-
tion (Doxil; ALZA Pharmaceuticals, Palo Alto, CA) was used.
Quercetin-loaded liposomes were prepared such that liposome
formulation was identical to Doxil, and as has been described [14].
Doxorubicin-loaded micelles were prepared as described [24].
Briefly, first PEG2000-DSPE micelles were prepared using a lipid
film hydration method. The lipid film was formed from a
chloroform solution of PEG2000-DSPE by removal of the organic
solvent by rotary evaporation followed by freeze-drying. The film
was hydrated with 10 mM PBS pH 7.4 at room temperature and
mixed using a vortex device for 5 min to give a final lipid
concentration of 40 mg/ml. The PEG2000-DSPE micelles were
then mixed with equal volume of drug solution (4 mg/ml) and
incubated at room temperature for 1 h. Free doxorubicin was
separated from the doxorubicin-micelle solutions using Amicon
centrifuge filters (MWCO=30 kDa). The micellar doxorubicin
concentration was 2 mg/ml after diluting the micelles with
methanol using a Labsystems Multiskan MCC/340 microplate
reader (Labsystems and Life Sciences International, UK) at
excitation and emission wavelengths of 485 and 590 nm,
respectively. The micelle size (hydrodynamic diameter) was
measured by dynamic light scattering (DLS) using a N4 Plus
Submicron Particle System (Coulter Corporation, Miami, FL,
USA) and was found to be 17.062.1 nm. The zeta-potential was
221.764.3 mV.
Quercetin-loaded micelles were also prepared using a lipid film
hydration method. Briefly, 0.6 mg of quercetin (1 mg/mL solution
in methanol) was added to polyethylene-glycolphosphatidyl-
ethanolamine (PEG2000-PE) solutions in chloroform, and a lipid
film was formed in a round-bottomed flask by solvent removal on
a rotary evaporator. The lipid film was then rehydrated with 1 mL
of phosphate buffered saline (pH 7.4) to obtain final lipid
concentration 5 mM. After mixing using a vortex device for
15 min at room temperature, the unincorporated quercetin was
removed by filtration of the micelle suspension through 0.2 mm
membrane filters. The micellar loading efficiency of quercetin was
100% (as for quercetin-loaded liposomes, 0.6 mg of quercetin was
loaded in each administered dose). The micelle size was
17 nm62.1 nm. The zeta-potential was -21.764.3 mV.
Tumor specimen retrieval
For Phases 1–3, tumors were removed from the animal and
sectioned perpendicularly to the direction of electrode insertion.
Tissue samples were split and processed for gross pathologic
assessment of tumor coagulation, and for histopathology, immu-
nohistochemistry, fluorescent microscopy, or doxorubicin quanti-
fication, as below.
Confocal microscopy and fluorescent quantification
Tumor sections were flash frozen in optimal cutting tempera-
ture (OCT) media, to allow analysis of fluorescence. Tissues were
sectioned at a thickness of 5 mm. For each tumor one slide was
stained for H&E for gross pathology comparison and slides
prepared for confocal fluorescent microscopy were counterstained
with DAPI nuclear staining. A Zeiss LSM 510 Inverted Live-Cell
Confocal System (Carl Zeiss Microscopy, Thornwood, NY) was
used for image acquisition and tiling. In brief, slides were
counterstained with Gold anti-fade reagent with DAPI (Life
Technologies, Grand Islands, NY) and stored overnight, followed
the next day with image acquisition. For each sample, at 106and
406 magnification, a minimum of 100 fields were imaged and
automatically tiled by the microscope software, Ziess LSM image
examiner (Carl Zeiss Microscopy). Tiled images allowed subjective
assessment and quantification of slices of the tumor section that
encompassed the center, periablational rim and tumor edge.
Images were then quantified for fluorescence using Volocity 6.0
software (PerkinElmer, Waltham, MA). For each tumor section,
the peak values, means and sums of each fluorescent color surface
area count were quantified. Where ‘‘peak values’’ represent the
area with highest uptake, typically the periablational rim (as
confirmed by duplicate H&E slides), ‘‘means’’ represent the
average fluorescent surface area count per HPF and the ‘‘sums’’
represent the area under the curve (AUC) or total fluorescent
surface area of a certain color in an entire section.
Effect of Nanodrug Carrier on RF Tumor Ablation Therapy
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To assess gross tumor coagulation, one half of each sample was
incubated in 50 ml of PBS with 1 mg of 2,3,5-triphenyltetrazolium
chloride (TTC, Sigma Aldrich) as has been previously described
[5]. Non-viable white tissue, representing the coagulation zone,
was identified and measured using manual calibers and recorded.
Immunohistochemical staining
Tumor samples were placed in cassettes containing the central
section of tumor. All tissues were fixed in 10% formalin overnight
at 4uC, embedded in paraffin, and sectioned at a thickness of
5 mm. Tissues were stained with H&E for gross pathology. For
Phase 2, at least 3 samples from each treatment group underwent
immunohistochemical staining using previously described tech-
Figure 1. Confocal tiled Imaging for fluorescent surface area quantitation in R3230 tumors sacrificed at 4 hours post RF (106).
R3230 tumors were treated with RF alone, followed by IV injection of equal volumes of 3 fluorescent beads of different colors and sizes (purple
20 nm, red 100 nm, green 500 nm). Quantitation of tiled images of tumor sections (center, periablational rim and tumor margin) demonstrated
fluorescent bead accumulation in the periablational rim, with greatest uptake of 20 nm beads (D) followed by the 100 nm (C) beads followed by the
500 nm beads (B)( p ,0.05, all comparisons).
doi:10.1371/journal.pone.0102727.g001
Figure 2. Confocal Imaging of perivascular and interstitial fluorescent bead penetration in the periablational rim 24 hr after RF
ablation of R3230 tumors (406). R3230 tumors were treated with RF alone, followed by IV injection of 3 fluorescent beads of different colors and
sizes (purple 20 nm, red 100 nm, green 500 nm). 406 images of the periablational rim reveal deeper penetration of the 20 nm beads into the
intracellular spaces beyond the primary site of extravasation, outlining and mapping out the cells they are surrounding (D,E), whereas the majority of
the 100 nm (B) remain confined to the primary site of extravasation. Even less extravasation is seen for the 500 nm beads (C).
doi:10.1371/journal.pone.0102727.g002
Effect of Nanodrug Carrier on RF Tumor Ablation Therapy
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HSP70, (Stressgen, Chicago, MI) [25], to detect evidence of HSP
production, and HIF-1a (Abcam, Boston, MA) were used to detect
the a-subunit of HIF-1.
Specimen slides were imaged at the periablational rim at 106
and 406 magnification and analyzed using a Micromaster I
microscope (Fisher Scientific, Pittsburgh, PA) and Micron Imaging
Software (Westover Scientific, Inc., Mill Greek, WA) to determine
rim thickness and percent (%) cell positivity. Five random high
power fields were analyzed for a minimum of 3 specimens for each
parameter and scored in a blinded fashion to remove observer
bias. As an additional control to insure uniformity of staining,
whenever direct comparisons were made, immunohistochemical
staining was repeated with all relevant comparison slides stained at
the same time. Accuracy of the final data was verified by the senior
author, who was blinded to treatment group.
Drug quantification in harvested tissues
Doxorubicin inherent fluorescent properties were used to
quantify drug accumulation in tumor and liver samples, as
described [5]. In Phase 3, tissue was harvested from the ablated
tumor, and remote, untreated tumor and untreated liver as
controls. Tissues were weighed, and homogenized in acid alcohol
(0.3N HCL, 70% EtOH), and doxorubicin was extracted for 24 hr
at 4uC. Doxorubicin extracted from tissue homogenate superna-
tant samples was quantified by fluorometry with an excitation
wavelength of 470 nm and intensity of emission measured at
590 nm and plotted on a standard curve.
Statistical Analysis
The Microsoft Office 2010 Excel software (Microsoft, Red-
mond, WA) was used for statistical analysis. All data were provided
as mean plus or minus SD. Immunohistochemistry results and
fluorescence quantification were compared using analysis of
variance (ANOVA). Additional post-hoc analysis was performed
with paired, two-tailed Student’s T-test, if and only if, the analysis
of variance achieved statistical significance. A P value of less than
0.05 was considered significant. The Kaplan–Meier method and
log-rank test were used for endpoint survival analysis. Given the
absence of censoring of our data, one-way analysis of variance was
then performed on the survival endpoints for each animal for the
comparisons reported. Pair-wise t tests (p,0.05; two-tailed test)
based on the least square means were subsequently performed
only if the overall P values were significant.
Results
Phase 1. Smaller beads (20 nm) have greater deposition
and deeper interstitial penetration than larger beads in
the post-RFA periablational zone
In R3230 tumors treated with RFA and IV fluorescent beads in
animals sacrificed at 4 and 24 hr, greatest deposition was observed
in the periablational rim, with peak uptake at 4 hr post-RFA for all
sizes of beads. At 4 hr post-RFA, 20 nm beads had the greatest
peak, sum and mean of fluorescence deposition, as depicted by
fluorescent surface area detected followed by 100 nm beads, with
the least uptake seen for 500 nm beads (TABLE 1). Similarly at
24 hr post-RFA, 20 nm beads had the greatest deposition as
compared to 100 nm and 500 nm beads (p,0.05 for all
comparisons, TABLE 1, FIGURE 1, 2). Similarly, for normal
liver we observed greater deposition of smaller beads (20 nm) in
the periablational margin compared to larger beads after RF
ablation. However, unlike the tumor model, bead deposition
peaked later at 24 hr post-RFA (TABLE 1).
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suppression of stress and hypoxia markers compared to
adjuvant liposomal Dox/Qu preparations
RFA combined with Mic-Dox led to greater suppression of
HIF-1a expression compared to RFA combined with Lipo-Dox as
measured by rim thickness in the periablational rim (45637 mm
vs. 129668 mm, respectively, p,0.04), with equal % cell positivity
(14.261.1 vs.13.662.1, respectively, p=0.7) (TABLE 2, FIG-
URE 3). Both adjuvant Mic-Dox and Lipo-Dox therapies resulted
in statistically significant reduction of HIF-1a expression as
compared to RFA alone groups (210685 mm and 37.964.3% at
24 hr, p,0.05 for all comparisons; TABLE 2, FIGURE 3).
RFA combined with any quercetin nanopreparation adminis-
tered at any time point reduced periablational HSP70 expression
compared to RFA alone control groups (p,0.01 for all
comparisons; TABLE 2). However, RFA micellar quercetin
preparations markedly reduced rim thickness of HSP70 expression
compared to RFA combined with liposomal quercetin for both
24 hr pre-RFA and 15 min post-RFA administration
(8536157 mm vs. 148886326 mm and 8596262 mm vs.
20896569 mm, respectively, p,0.03 for all comparisons) (FIG-
URE 4). With regard to timing of adjuvant nanodrug adminis-
tration, Mic-Qu markedly reduced rim thickness of HSP70
expression equally at both 24 hr pre- and 15 min post-RFA
administrations (8536157 mm and 8596262 mm, respectively,
p=NS). However, adjuvant Lipo-Qu resulted in the greatest
suppression of RFA-induced HSP70 expression when given 24 hr
pre-RFA, with significantly less effect on the rim thickness of
HSP70 expression when given 15 min post-RFA (148886326 mm
and 20896569 mm, respectively; p,0.01) (TABLE 2).
Phase 3. RF ablation combined with long-circulating
liposomal nanodrugs led to equal local tumor
coagulation and equal or better control of tumor growth
and animal endpoint survival compared to micellar
nanodrugs
Significantly greater tumor coagulation was achieved in
treatment groups combining RFA with any adjuvant nanopre-
parations of quercetin or doxorubicin, than by RFA alone at 24 hr
(all comparisons p,0.05, TABLE 2). Yet, no statistically signif-
icant difference in coagulation was observed based on type of drug
or nanopreparation used at 24 hr (TABLE 2).
Figure 3. Comparison of micellar and liposomal formulations on modulating local periablational target proteins (HIF-1a and
HSP70) 24 hr after RF ablation of R3230 tumor. (A) Micellar doxorubicin suppressed periablational HIF-1a expression to a greater degree than
(B) liposomal doxorubicin 24 hr after RF ablation (406). Similarly, (C) micellar quercetin suppressed ablation-induced periablational HSP70 expression
in R3230 tumor at 24 hr compared to (D) liposomal quercetin (106).
doi:10.1371/journal.pone.0102727.g003
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mean endpoint survival for animals treated with RFA/Lipo-Dox
was 49.869.1 d, including two animals that survived up to the 60
day post-treatment monitoring end-point. This was significantly
longer than RFA/Mic-Dox, which had a mean survival of
39.668.4 d (p,0.04, FIGURE 5). By contrast, RFA/Lipo-Qu
and RFA/Mic-Qu had similar animal endpoint survival profiles,
where RFA/Mic-Qu had a mean survival of 31.168.2 d
compared to 31.269.1 d with RFA/Lipo-Qu (p=0.9, FIG-
URE 5).
Phase 4. Contrasting intratumoral doxorubicin
accumulation kinetics for micellar and liposomal
preparations after RF ablation
At 1 hr post-RFA, there was minimal doxorubicin detected in
tumor samples of either Mic-Dox or Lipo-Dox groups. However,
at 4 hr post-RFA, intratumoral doxorubicin levels were approx-
imately 6-fold higher for RFA/Mic-Dox compared to RFA/Lipo-
Dox (0.000660.0002 mg/g vs. 0.000160.000024 mg/g, p,0.03).
Yet, at the later time points of 24 hr and 72 hr, RFA/Lipo-Dox
increased to a much greater degree than micellar doxorubicin
concentrations. This resulted in significantly higher levels of
intratumoral doxorubicin (approximately 17-fold) for long-circu-
lating liposomal doxorubicin delivery compared to RFA/Mic-Dox
(p,0.01 for all comparisons, TABLE 3). Specifically, at 24 hr
post-RFA, doxorubicin levels in the periablational rim were
1.0260.52 mg/g for RFA/Lipo-Dox compared to only
0.0660.02 mg/g for RFA/Mic-Dox (p,0.001). Similarly, at
72 hr post-RFA, intratumoral doxorubicin levels after RFA/
Lipo-Dox were 1.1760.52 mg/g, compared to RFA/Mic-Dox
0.0160.02 mg/g (p,0.001).
Discussion
There is increasing interest in developing treatment paradigms
that combine focal tumor ablation with adjuvant pharmacologic or
chemotherapeutic agents to address both challenges with residual
viable tumor from incomplete local treatment and difficulties in
achieving high concentrations of targeted drug delivery [18,26–
28]. Early studies combining RF ablation with a commercially-
available liposomal doxorubicin (Doxil) preparation reported
increases in local tumor coagulation, periablational drug uptake,
and reduced tumor growth in animal studies, and increased tumor
destruction in preliminary clinical studies [5,6,8,9]. Subsequent
studies have refined the approach, either through modification of
the drug payload or using thermosensitive preparations to facilitate
intratumoral drug release, though with mixed improvements in
treatment efficacy [11–13,17]. While most of these studies have
largely used 100 nm sized liposomes as the carrier model, more
recent studies on nanoparticle delivery (without ablation) suggest
improved carrier and drug penetration with smaller-sized prepa-
rations [20,29].
In our current study, smaller-sized particles (20 nm) adminis-
tered in combination with RF ablation did indeed result in greater
and deeper interstitial and perivascular penetration into the
periablational rim compared to larger (100 nm and 500 nm) sized
particles. Thus, our findings are consistent with uses of smaller-
sized carriers to overcome limitations in intratumoral and
interstitial drug delivery when using nanoparticles alone or in
combination with low-level hyperthermia (40–45uC) applications
[29,30]. For example, Tsukioke et al have reported deeper
interstitial penetration of micellar doxorubicin into tumor
spheroids as compared to liposomal doxorubicin [29]. Yet, our
results go well beyond these findings as we achieved a primary goal
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micellar preparations can be translated into markedly improved
modulation/suppression of specifically targeted tissue reactions in
the periablational rim. To wit, here ablation-induced expression of
both HIF-1a and HSP70 were independently suppressed to a
greater degree with micellar nanopreparations compared to their
liposomal counterparts in terms of spatial distribution. Specifically,
micellar nanodrugs specifically reduced the geographic extent of
marker expression (i.e., rim thickness) in the periablational rim,
highlighting greater tissue penetration micellar preparations with
concurrent greater spatial distribution of the desired biochemical
modulation.
While these results are exciting in achieving a primary goal of
using refined nanodrug paradigms to target specific cellular
reactions, it must be acknowledged that these gains in interstitial
penetration and suppression of local tissue reactions do not
necessarily translate into improvements in all desired outcome
metrics in cancer therapy. Along these lines, in our study micellar
preparations had similar or inferior effects on curbing tumor
growth and promoting animal survival and likewise micellar
preparations did not increase local ablation-induced tumor
coagulation compared to liposomal preparations at 24 hr. This
reinforces our understanding that local effects of tumor coagula-
tion and periablational proteomic reactions may also not directly
translate into reduction in tumor growth and gains in animal
endpoint survival outcomes.
To account for the results we observed, we hypothesize that
marked, but incomplete reduction of HSP or HIF-1a may be
insufficient to induce complete tumor destruction at 24 hr and
that, the ability of each drug to increase local coagulation may be
susceptible to a threshold effect, with only a certain amount of
drug required to target the partially injured remaining cells in the
periablational rim. However, other longer-term effects on growth
in the remaining untreated tumor may reflect a more complex
reality where differences in nanocarrier release and drug uptake
that are greater with long-circulating liposomal formulations [31]
may very well be of primary importance for overall survival.
Indeed, our results are concordant with previously reported
findings by Yang et al, where RFA combined with liposomal
paclitaxel (an apoptosis enhancer) resulted in greater apoptosis (as
measured by caspase 3), yet did not suppress tumor growth to a
similar extent as liposomal doxorubicin [13]. Conversely, with
increasing evidence that some reactions (such as increased HIF-1a)
in the periablational rim may stimulate growth in distant tumor,
successful modulation of local tissue reactions may assume
increasing clinical relevance as its own endpoint separate from
tumor growth [32–34].
Our study adds to the growing body of evidence supporting the
notion that it is the variable nanodrug delivery kinetics that are
likely to be primarily responsible for the way that different
nanopreparations induce better or worse effects on specific
outcome metrics [17,35]. For example, while greater intratumoral
doxorubicin uptake was observed with micelles compared to
liposomes early (4 hr) after RF ablation, liposomes delivered
significantly greater doxorubicin to the treated tumor over a
longer period of time (24–72 hr post-treatment). Therefore, while
micellar preparations had a greater effect on our specific targets
(HIF-1a and HSP70), these markers also peak early (4–24 hr post-
RFA) and may be more susceptible to early drug delivery. In
contrast, if the overall amount of drug delivery to the tumor is the
primary goal, then long-circulating liposomal preparations are
superior carriers. Greater overall tumor exposure to accumulating
doxorubicin may explain the greater animal endpoint survival
observed with RFA/liposomal doxorubicin. Along these lines,
recently, Andriyanov et al reported corroborating findings when
comparing RF ablation combined with conventional long-circu-
lating stealth PEG-ylated liposomal doxorubicin (i.e., Doxil) to
fast-releasing 100 nm thermosensitive liposomal doxorubicin (i.e.,
ThermoDox), in which prolonged slow drug uptake resulted in a
greater reduction in long-term tumor growth compared to early
flooding of the tumor with intratumoral nanodrug [17]. Indeed,
we posit that longer drug circulation, and therefore exposure time,
may take on greater importance for processes that are likely to
occur over a variable relatively longer time frame in the target
Figure 4. RF ablation combined with micellar quercetin suppresses periablational HSP70 expression more than a liposomal
nanocarrier. Interestingly, in addition to the observed superior inhibitory effect of adjuvant micellar quercetin over adjuvant liposomal quercetin,
regardless of timing of admininstration (pre-RFA or post-RFA), micellar adjuvant therapy is equally effective when given pre- or post-RFA
(853.076156.59 mm and 859.426261.51 mm). However, adjuvant liposomal quercetin shows significantly greater HSP70 inhibition when given pre-
RFA as compared to tumors treated with liposomal quercetin post-RFA (14888.016325.53 mm and 2088.586568.54 mm).
doi:10.1371/journal.pone.0102727.g004
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PLOS ONE | www.plosone.org 8 August 2014 | Volume 9 | Issue 8 | e102727Figure 5. Comparison of animal endpoint survival for micellar and liposomal doxorubicin or quercetin formulations when
combined with RF ablation of R3230 tumors. (A) RF/Lipo-Dox resulted in the greatest animal survival (49.869.1 d), followed by RFA/Mic-Dox
(39.668.4 d). (B) RFA combined with either micellar quercetin or liposomal quercetin resulted in the same mean animal survival (31.168.2 d and
31.269.1 d, respectively).
doi:10.1371/journal.pone.0102727.g005
Table 3. Periablational intratumoral doxorubicin accumulation for liposomal and micellar nanocarriers combined with RF ablation
over time.
Doxorubicin accumulation in RF ablated tumors (mg/g)
Time post RF RF+Lipo Dox RF+Mic Dox
Mean ± SD Mean ± SD
1 hour 0.0000008160.0000003 0.0000000760.0000001
4 hours 0.000160.000024 0.000660.000174*
24 hours 1.0260.517* 0.0660.024
72 hours 1.1760.243* 0.0160.013
*= p ,0.05 when compared to the other treatment group.
doi:10.1371/journal.pone.0102727.t003
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effective when cells are in the G2 phase of replication, and cells in
and around the ablation zone are likely to enter the G2 phase at
variable time points after ablation [36]). Having high concentra-
tions of doxorubicin in the serum when various cells enter this
point of the cell cycle over a period of days may well represent the
best chance to ensure that efficacious drug concentrations are
present when most needed.
Additional potentially useful pharmacologic observations were
noted in our study. For quercetin nanopreparations, we also found
a wider window of efficacious administration with micellar
preparations than may have been expected given the well-known,
relatively short (2–3 hr half-life) plasma kinetics for these smaller
vehicles [37]. Specifically, we demonstrated equivalent responses
and tumor coagulation when micellar quercetin was given
between 24 hr pre- to 15 min post-RF ablation compared to the
liposomal formulation where optimal HSP70 suppression was
observed only when given 24 hr pre-RFA. Thus, our results
suggest that intratumoral concentrations are primary over plasma
kinetics and that likely very little drug is needed to achieve the
desired HSP reduction – provided it is successfully delivered to the
desired spatial location. Additionally, we observed variable timing
of accumulation for smaller fluorescent bead particles between
tumor and normal liver, where peak fluorescence was observed at
24 hr post-RFA in normal liver. This suggests that even with
equivalent outcomes, some types of nanocarriers, with ideal
therapeutic windows tailored to specific tissues, may offer clinically
relevant and practical advantages.
Ultimately, our findings suggest that several different factors
need to be considered when developing combination therapy
paradigms. Optimal choice of carrier type and drug payload will
likely involve both identifying goals of treatment and prioritizing
outcome metrics (e.g., local suppression of a specific cytokine such
as HIF-1a or control of tumor growth). Tumor and tissue-specific
characteristics, and differences in carrier and drug pharmacoki-
netics will factor into the practical considerations of when to time
peri-ablation drug administration. Thus, the choice of nanopar-
ticles should ultimately likely be tailored to achieve specific goals in
specific tissues, as optimal carriers may differ depending on
whether modulation of local periablational processes or growth
suppression of untreated tumor is required.
We acknowledge several limitations with our study. Fluorescent
beads were commercially acquired and the number of beads per
volume was pre-determined by the manufacturer and was not
likely not identical between different particle sizes. Yet, we
controlled for the key variable drug concentration in all of our
subsequent experiments as the active drug (i.e., 1 mg of
doxorubicin loaded in 0.5 ml) was given precedence to the
number of particles in the micellar or liposomal vehicle. Thus, as
expected, fluorescent beads of a smaller size had a consistently
higher concentration than larger-sized beads. Additionally,
although the R3230 model used for these studies is a well-
characterized tumor model, results demonstrated may be specific
to the model and should be interpreted and applied to other
scenarios and models with caution, mirroring our call for tailoring
nanopreparations to different tumor types and scenarios. Differ-
ences also exist in pharmacokinetic profiles between the fluores-
cent beads and correspondingly sized nanopreparations (i.e.,
20 nm beads vs. 20 nm micelles). Therefore, interpretation and
correlation of results between fluorescent beads and nanoprepara-
tions must be made carefully. Furthermore, in survival studies, we
did not include an RFA alone treatment arm, as prior studies have
clearly demonstrated a survival benefit for combination therapy
arms (liposomal doxorubicin or quercetin) [9,38]. Finally, tumor
coagulation for micellar doxorubicin in this study differs from
results obtained in an earlier study using a small liposome
preparation (,40 nm), where high levels of intratumoral doxoru-
bicin accumulation but smaller amounts of tumor coagulation
were reported compared to a 100 nm preparation. Differences in
results may represent variable micellar stability due to differences
in doxorubicin loading doses [29], and emphasizes that results
from experimental and clinical studies using combination para-
digms are critically dependent on developing the appropriate
nanopreparations for the right application.
In conclusion, when combined with RF ablation, smaller-sized
particles have superior deeper tissue penetration and therefore can
potentially achieve more effective local molecular modulation of
specific post-ablation reactions including heat shock protein and
HIF-1a expression, with a wider window of administration as
compared to larger (100 nm) particles. However, larger-sized long-
circulating particles can result in greater overall long-term
intratumoral drug accumulation and reduced tumor growth.
Therefore, different nanodrug carriers provide specific advantages,
in part based upon size and circulation kinetics, which should be
considered when formulating strategies to achieve optimal
combination therapies with tumor ablation.
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